• español
    • English
    • português
  • español 
    • español
    • English
    • português
  • IRIS PAHO Inicio
  • Sitio de la OPS
  • Índices
  • Todas las Colecciones
  • Sobre IRIS
  • Memoria Institucional
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ver ítem 
  •   IRIS PAHO Inicio
  • 1.PAHO Headquarters / Sede de la OPS
  • Scientific Journals and Newsletters / Revistas Científicas y Boletines
  • Pan American Journal of Public Health
  • Ver ítem
  •   IRIS PAHO Inicio
  • 1.PAHO Headquarters / Sede de la OPS
  • Scientific Journals and Newsletters / Revistas Científicas y Boletines
  • Pan American Journal of Public Health
  • Ver ítem

Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus

Thumbnail
Ver/Abrir
5139.pdf (64.06Kb)
Fecha
2001
Autor
Anon
Metadatos
Mostrar el registro completo del ítem
Resumen
In February 1994, a clinical trial by the Pediatrics AIDS Clinical Trials Group (PACTG 076) demonstrated, for the first time, that it was possible to reduce the risk of vertical transmission of human immunodeficiency virus type 1 (HIV-1) by nearly 70 percent by means of a triple therapeutic regimen: 1) oral zidovudine (ZDV) beginning anytime between the 14th and 34th week of gestation until the end of pregnancy; 2) intravenous ZDV during pregnancy, and 3) administration of oral ZDV to neonates during the first 6 weeks of life. Later, epidemiologic studies performed in the United States of America and France showed that this regimen drastically reduced perinatal transmission in clinical practice. Since then, important strides have been made, not only in terms of treatment (new drugs and highly effective therapeutic regimens) and diagnosis (tests that can measure the viral load), but also in terms of an increased understanding of the pathogenesis of perinatal transmission of HIV-1. This report contains: a) a review of special considerations to be kept in mind when administering antiretroviral agents to pregnant women; b) a current overview of the results of clinical and epidemiologic trials dealing with the prevention of perinatal transmission of HIV-1; c) a look at the use of tests for measuring HIV-1 RNA (viral load) during pregnancy; d) the most recent recommendations on the use of antiretroviral chemoprophylaxis and elective cesarean section for reducing perinatal viral transmission. These recommendations apply to the United States, and other countries may prefer to use different approaches.(AU)
Título traducido
Recommendations on the use of antiretroviral agents in pregnant women infected with HIV-1
Series
Rev Panam Salud Publica;9(5),mayo 2001
Tema
VIH-1; Transmisión perinatal; Antirretrovíricos; Prevención y Mitigación; Cesárea
URI
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=pt&nrm=iso&tlng=es
https://iris.paho.org/handle/10665.2/7834
Cita
Anon (2001) Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus. Rev Panam Salud Publica;9(5) 345-354,mayo 2001. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=pt&nrm=iso&tlng=es
Colecciones
  • Pan American Journal of Public Health

Listar

Todo IRIS PAHOComunidades & ColeccionesFecha de publicaciónAutoresTítulosMateriasTítulo de SerieTipo de materialIdiomaCategoríaUnidad Técnica/Oficina de PaísEsta colecciónFecha de publicaciónAutoresTítulosMateriasTítulo de SerieTipo de materialIdiomaCategoríaUnidad Técnica/Oficina de País

Estadísticas

Ver Estadísticas de uso

Organización Panamericana de la Salud
Organización Mundial de la Salud. Oficina Regional para las Américas
525 Twenty-third Street, N.W., Washington, D.C. 20037, Estados Unidos de América
Tel.: +1 (202) 974-3000 Fax: +1 (202) 974-3663
email: libraryhq@paho.org

Links

  • Publicaciones destacadas de la OPS
  • Biblioteca Digital de la OMS (IRIS)
  • Biblioteca Virtual en Salud (BVS)
  • Global Index Medicus (GIM)